Acrylamide

Acrylamide

SCHEMBL7045841

C=CC(=O)N1CCOCC1.C=CC(N)=O

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.45
TP53 P04637 1/20 0.45
KMT2A Q03164 1/20 0.45
TSHR P16473 2/20 0.44
ALDH1A1 P00352 1/20 0.44
FGFR4 P22455 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA9 Q16790 1/20 0.42
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.39
MMP1 P03956 1/20 0.39
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20547256 0.92 MEN1 (0.52) MEN1TP53KMT2ATSHRALDH1A1
SCHEMBL36422 0.92 MEN1 (0.52) MEN1TP53KMT2ATSHRALDH1A1
SCHEMBL12764462 0.90 SMN1; SMN2 (0.52) MEN1TP53KMT2ATSHRSMN1; SMN2
Charcoal, Activated SCHEMBL30277426 0.90 MEN1 (0.50) MEN1TP53KMT2ATSHRALDH1A1
SCHEMBL28170140 0.90 MEN1 (0.50) MEN1TP53KMT2ATSHRALDH1A1
Hydrochloric Acid SCHEMBL23497791 0.90 MEN1 (0.50) MEN1TP53KMT2ATSHRALDH1A1
SCHEMBL2791593 0.90 SMN1; SMN2 (0.52) MEN1TP53KMT2ATSHRSMN1; SMN2
Bromide SCHEMBL31199104 0.90 MEN1 (0.50) MEN1TP53KMT2ATSHRALDH1A1
Hydroxyl Radical SCHEMBL28076004 0.90 MEN1 (0.50) MEN1TP53KMT2ATSHRALDH1A1
SCHEMBL28120480 0.88 MEN1 (0.48) MEN1TP53KMT2ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3110564-A1 RADIATION CURABLE INKS AND COATINGS CONTAINING DIACETONE ACRYLAMIDE Sun Chemical Corporation (US) 2017-01-04 EP disclosed
US-20160340529-A1 RADIATION CURABLE INKS AND COATINGS CONTAINING DIACETONE ACRYLAMIDE SUN CHEMICAL CORPORATION (US) 2016-11-24 US disclosed
CN-105732541-A Bifunctional monomer and preparation method thereof 无锡海特圣大光电材料科技有限公司 2016-07-06 CN disclosed
WO-2015131029-A1 RADIATION CURABLE INKS AND COATINGS CONTAINING DIACETONE ACRYLAMIDE SUN CHEMICAL CORPORATION (US) 2015-09-03 WO disclosed
US-6825339-B2 IMMOBILIZATION TO POROUS SOLID SUPPORT; OXIDATION USING IODINE IN GLACIAL ACETIC ACID PROLIGO, LLC 2004-11-30 US disclosed
US-6623703-B1 Efficient synthesis of oligonucleotides PROLIGO, LLC 2003-09-23 US disclosed
US-20030176690-A1 Apparatus for preparing polynucleotides on a solid support PROLIGO, LLC 2003-09-18 US disclosed
US-6590092-B1 Oligonucleotide synthesis wherein nucleotides are incorporated onto a substrate of given formula; can be used irrespective of the first RNA or DNA nucleotide to be synthesized and irrespective of the monomer reagent used cleavage using a NGO NAM Q (US) 2003-07-08 US disclosed
US-6469157-B1 USING A COLUMN CONTAINING AN IMMOBILIZED SOLID SUPPORT THAT IS FUNCTIONALIZED FOR POLYNUCLEOTIDE SYNTHESIS PROLIGO LLC 2002-10-22 US disclosed
US-20020103365-A1 PROCESS FOR THE SYNTHESIS OF NUCLEIC ACIDS ON A SOLID SUPPORT AND COMPOUNDS WHICH ARE USEFUL IN PARTICULAR AS SOLID SUPPORTS IN THE SAID PROCESS PROLIGO, LLC 2002-08-01 US disclosed
US-5869643-A DEPROTECTION, FIRST WASHING, ADDING BASE TO FORM INTERNUCLEOTIDE BONDING, SECOND WASHING, OXIDATION AND THIRD WASHING GENSET (FR) 1999-02-09 US disclosed
EP-0707592-B1 PROCESS FOR SOLID SUPPORT NUCLEIC ACID SYNTHESIS AND COMPOUNDS USEFUL AS SOLID SUPPORTS IN SAID PROCESS GENSET SA (FR) 1997-09-03 EP disclosed
EP-0658566-B1 Process of polynucleotide preparation on a solid support and apparatus allowing it to be carried out GENSET SA (FR) 1997-07-02 EP disclosed
EP-0707592-A1 PROCESS FOR SOLID SUPPORT NUCLEIC ACID SYNTHESIS AND COMPOUNDS USEFUL AS SOLID SUPPORTS IN SAID PROCESS GENSET SA (FR) 1996-04-24 EP disclosed
EP-0658566-A1 Process of polynucleotide preparation on a solid support and apparatus allowing it to be carried out GENSET SA (FR) 1995-06-21 EP disclosed
WO-1995001987-A1 PROCESS FOR SOLID SUPPORT NUCLEIC ACID SYNTHESIS AND COMPOUNDS USEFUL AS SOLID SUPPORTS IN SAID PROCESS GENSET (FR) 1995-01-19 WO disclosed
EP-0206913-B1 SUPPORTS, THE PREPARATION OF THESE SUPPORTS, INTERMEDIATES OBTAINED, THEIR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES, AND NUCLEOSIDES AND OLIGONUCLEOTIDES LINKED TO THE SUPPORTS ROUSSEL-UCLAF (FR) 1989-09-13 EP disclosed
EP-0208599-B1 SUPPORTS, THEIR PREPARATION AND INTERMEDIATES OBTAINED, THEIR USE IN THE SYNTHESIS OF OLIGONUCLEOSIDES AND THE NUCLEOSIDES SO OBTAINED, AND OLIGONUCLEOTIDES LINKED TO THE SUPPORTS ROUSSEL-UCLAF (FR) 1989-08-30 EP disclosed
US-4812512-A SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES ROUSSEL UCLAF (FR) 1989-03-14 US disclosed
US-4780504-A POLYLACTAMS LINKED TO SILICA MICROPELLETS ROUSSEL UCLAF (FR) 1988-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103365-A1 PROCESS FOR THE SYNTHESIS OF NUCLEIC ACIDS ON A SOLID SUPPORT AND COMPOUNDS WHICH ARE USEFUL IN PARTICULAR AS SOLID SUPPORTS IN THE SAID PROCESS POLR2H, POLR2E, POLRMT MEN1 3635/4885TP53 1341/4885KMT2A 394/4885
US-20030176690-A1 Apparatus for preparing polynucleotides on a solid support POLN, POLRMT, POLM MEN1 4116/4885TP53 2884/4885KMT2A 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.